Update from the Working Group on Cardiovascular Pharmacotherapy

Heinz Drexel, Chairperson

August 2019
Agenda

➢ Nucleus composition
➢ Membership
➢ Congresses & Meetings
➢ Education
➢ Research & publication
➢ 2020 Elections
## Nucleus 2018-2020 composition

<table>
<thead>
<tr>
<th>Nucleus Member Role</th>
<th>Start mandate</th>
<th>End mandate</th>
<th>First Name</th>
<th>Last Name</th>
<th>Country of Work</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairperson</td>
<td>01/09/2018</td>
<td>31/08/2020</td>
<td>Heinz</td>
<td>Drexel</td>
<td>Austria</td>
</tr>
<tr>
<td>Vice-Chairperson</td>
<td>01/09/2018</td>
<td>31/08/2020</td>
<td>Alexander</td>
<td>Niessner</td>
<td>Austria</td>
</tr>
<tr>
<td>Past-Chairperson</td>
<td>01/09/2018</td>
<td>31/08/2020</td>
<td>Basil S</td>
<td>Lewis</td>
<td>Israel</td>
</tr>
<tr>
<td>Treasurer</td>
<td>01/09/2018</td>
<td>31/08/2020</td>
<td>Thomas Andersen</td>
<td>Schmidt</td>
<td>Denmark</td>
</tr>
<tr>
<td>Secretary &amp; Web Editor</td>
<td>01/09/2018</td>
<td>31/08/2020</td>
<td>Gianluigi</td>
<td>Savarese</td>
<td>Sweden</td>
</tr>
<tr>
<td>Ordinary nucleus member</td>
<td>01/09/2018</td>
<td>31/08/2022</td>
<td>Keld Per</td>
<td>Kjeldsen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Ordinary nucleus member</td>
<td>01/09/2018</td>
<td>31/08/2022</td>
<td>Juan Luis</td>
<td>Tamargo</td>
<td>Spain</td>
</tr>
<tr>
<td>Ordinary nucleus member</td>
<td>01/09/2018</td>
<td>31/08/2022</td>
<td>Christian Tobias</td>
<td>Torp-Pedersen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Ordinary nucleus member</td>
<td>01/09/2018</td>
<td>31/08/2022</td>
<td>Anne Grete</td>
<td>Semb</td>
<td>Norway</td>
</tr>
<tr>
<td>Ordinary nucleus member</td>
<td>01/09/2018</td>
<td>31/08/2022</td>
<td>Claudio</td>
<td>Borghi</td>
<td>Italy</td>
</tr>
<tr>
<td>Ordinary nucleus member</td>
<td>01/09/2018</td>
<td>31/08/2022</td>
<td>Iris</td>
<td>Baumgartner</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Ordinary nucleus member</td>
<td>01/09/2016</td>
<td>31/08/2020</td>
<td>Sven</td>
<td>Wassmann</td>
<td>Germany</td>
</tr>
<tr>
<td>Ex-Officio</td>
<td>01/09/2016</td>
<td>31/08/2020</td>
<td>Giuseppe M C</td>
<td>Rosano</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Ex-Officio</td>
<td>01/09/2018</td>
<td>31/08/2020</td>
<td>Juan Carlos</td>
<td>Kaski</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Ex-Officio</td>
<td>01/09/2018</td>
<td>31/08/2020</td>
<td>Stefan</td>
<td>Agewall</td>
<td>Norway</td>
</tr>
<tr>
<td>Affiliated Members</td>
<td>01/09/2018</td>
<td>31/08/2020</td>
<td>Claudio</td>
<td>Ceconi</td>
<td>Italy</td>
</tr>
</tbody>
</table>

Contact the nucleus members [online here](#).
Membership evolution since 2010

<table>
<thead>
<tr>
<th>Year</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 2010</td>
<td>185</td>
</tr>
<tr>
<td>Jan 2011</td>
<td>199</td>
</tr>
<tr>
<td>Jan 2012</td>
<td>210</td>
</tr>
<tr>
<td>Jan 2013</td>
<td>251</td>
</tr>
<tr>
<td>Jan 2014</td>
<td>284</td>
</tr>
<tr>
<td>Jan 2015</td>
<td>309</td>
</tr>
<tr>
<td>Jan 2016</td>
<td>382</td>
</tr>
<tr>
<td>Jan 2017</td>
<td>495</td>
</tr>
<tr>
<td>Jan 2018</td>
<td>568</td>
</tr>
<tr>
<td>Jan 2019</td>
<td>645</td>
</tr>
<tr>
<td>July 2019</td>
<td>683</td>
</tr>
</tbody>
</table>
Membership

Gender

- Male: 77%
- Female: 23%

Age

- < 40: 216
- 40 < 50: 141
- 50 < 60: 124
- 60 < 65: 82
- > 65: 132

Country of Work

- Italy: 33
- United Kingdom: 31
- Germany: 27
- Spain: 24
- Ukraine: 19
- Russian Federation: 19
- Portugal: 19
- Netherland: 19
- United States: 18
- Denmark: 18
- Poland: 16
- France: 16
- Austria: 16
- Norway: 14
- Egypt: 14
- Switzerland: 13
- Israel: 13
- India: 13
- Turkey: 11
- Greece: 11
- Serbia: 10
- Croatia: 10
- Belgium: 10

Stage in Career

- Practicing: 430
- In training: 97
- Retired: 27
- Student: 15

ESC Membership Region

- NCS Countries: 81%
- ACS Countries: 15%
- Rest of World: 4%
Membership
All ESC Working Groups Overview – July 2019

- W.G. on Cardiac Cellular Electrophysiology
- W.G. on Atherosclerosis and Vascular Biology
- W.G. on Thrombosis
- W.G. on Grown-up Congenital Heart Disease
- W.G. on CV Pharmacotherapy
- W.G. on Myocardial & Pericardial Diseases
- W.G. on Cellular Biology of the Heart
- W.G. on e-Cardiology
- W.G. on Coronary Pathophysiology and Microcirculation
- W.G. on Myocardial Function
- W.G. on Aorta & Peripheral Vascular Diseases
- W.G. on Pulmonary Circulation & Right Ventricular Function
- W.G. on Development, Anatomy and Pathology
- W.G. on CV Surgery
- W.G. on CV Regenerative & Reparative Medicine
EuroCVP 2020 – May, Vienna

Our EuroCVP 2020 congress program is designed to attract everybody involved in cardiovascular pharmacotherapy. A major aim is to attract young cardiologists. Not contradictory, one focus will be on pharmacotherapy in older people.

The topics will be metabolic disease, i.e. dyslipidaemia and diabetes, congestive heart failure, antithrombotic therapy and many others. The formats include formal update lectures, pro-contra- debates, and case stories. The latter will allow for ample discussion. A major point is to present and discuss the new 2019 guidelines of the ESC.

At the end of the congress, the participant will have an up-to-date knowledge of cardiovascular pharmacotherapy.

More information will be available for members in September 2019.
NEW! Training Course on Pharmacotherapy in Older People 25 October, London, UK

In Europe and throughout the world, the proportion of older people is increasing dramatically. Cardiovascular pharmacotherapy in these patients poses complex and exciting challenges particularly in relation to co-morbidities, drug interactions and differences in cardiac metabolism.

Cardiovascular drugs are among the most commonly administered therapeutic agents in the elderly, including diuretics, antihypertensives, NOACs, antiarrhythmics, lipid lowering drugs and glucose lowering drugs. All these different medications can lead to increased frailty and should not be prescribed on a one-size-fits-all-basis.

This new course will provide participants insight into the complexities of contemporary pharmacotherapy in the elderly and help practitioners to deliver more personalized, effective therapy in this patient population. It will be highly interactive, with clinical case based presentations, debates and ample time for discussion.

Register online (fees start at 80€)
Education

All About Clinical Trials – EuroCVP 12-13 December 2019, Stockholm, Sweden
In collaboration with the Karolinska Institute

Focus on
• Methodological issues regarding the design, conduct and interpretation of clinical trials
• New types and trends of trials required by regulator

At the end of the course delegates will have improved their knowledge in:
• Designing and planning successful clinical trials
• Evaluating and following the correct processes and regulatory procedures
• Effectively analysing and interpreting trial data using clinical trials presented at the latest cardiovascular scientific meetings as examples

Register online (fees start at 50€)
Research & publications

European Heart Journal – Cardiovascular Pharmacotherapy
The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is the official journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy. The journal aims to improve the pharmacological treatment of patients with cardiovascular disease through interpreting and integrating new scientific developments within this area.

It publishes original articles concerning clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews.

Fast Facts
• Editor-in-Chief: Stefan Agewall FESC, NO
• Current volume: 5 (year 2019)
• Issues per subscription: 4
• Impact Factor 2018: 6.723

Subscribe
Research & publications

ESC Handbook on Cardiovascular Pharmacotherapy

Edited by Juan Carlos Kaski and Keld Per Kjeldsen

The handbook provides up-to-date information on pharmacotherapy for cardiovascular disease prevention, and treatment of cardiovascular disease, including ischaemic heart disease, heart failure, arrhythmias, and structural heart disease.

The handbook represents essential reading for cardiologists, general practitioners, internal medicine specialists, anaesthetists, clinical pharmacologists, geriatricians, obstetricians, and cardiovascular nurse consultants. Junior doctors and trainees in all these specialties are also likely to find this book of help.

The print edition comes with full access to the online version that will be updated at yearly intervals to keep it up to date.

Order your copy
Research & publications

Position papers published

• Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke (P Sulzgruber et. al): July 2019

• Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. (G Rosano et. al): July 2018

• Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy (A Niessner et. al) : June 2018

Position papers in writing

• Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases (G. Savarese et. al)

• Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of the European Society of Cardiology (I Hollan et. al)
Advocacy

Angina Awareness Programme

Coordinators: Prof. Giuseppe Rosano & Prof. Heinz Drexel

The Angina Awareness Programme was launched in November 2017 in order to raise awareness amongst physicians on the need for optimal medical therapy in patients with angina pectoris and to increase the awareness of the lay public on the importance of angina, its consequences and its possible treatments.

The overarching objective of the Angina Awareness Program is to drive measurable change in angina management in order to improve patient outcomes. Through awareness generation, the Working Group aims to:

- Make management of angina and its risk factors a global health priority
- Clarify patient management pathways (in conjunction with ESC Guidelines)
- Support National Societies to increase angina awareness at a national level
- Support Cardiac Societies to institutionalise and formalise angina and coronary artery disease management
- Actively engage patients and their careers in the management of these chronic conditions
2020 Elections

Elections for the following positions will be open in 2020
- Vice-Chairperson
- Nucleus member

Nucleus Member elections – timeline
Call for candidates
Voting
Announcement of results
April 2020
May – June 2020
July 2020

Nucleus members are elected by the members of that same Working Group whose country of work is an ESC Member Country. Further information on eligibility criteria & election process will be available in the call for candidates.